查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1335275

筆用針頭的世界市場

Pen Needles
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 432 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球筆用針頭市場將達到 48 億美元

在COVID-19之後的商業環境發生變化的情況下，全球筆用針頭市場預計2022年為24億美元，預計到2030年將達到48億美元，2022年至2030年的年複合成長率為9.2% 。預計將成長。本報告分析的細分市場之一“標準”預計複合年成長率為 7.2%，到分析期結束時將達到 26 億美元。鑑於大流行後的持續復甦，未來八年安全領域的年複合成長率修正為 11.9%。

美國市場預計將成長7.691億美元，中國年複合成長率為10.3%

2022年美國筆針市場預計為7.691億美元。中國作為世界第二大經濟體，預計到2030年市場規模將達到3.817億美元，2022年至2030年復合年成長率為10.3%。其他值得注意的地域市場包括日本和加拿大，預計 2022 年至 2030 年將分別成長 7.9% 和 8%。在歐洲，德國的年複合成長率預計約為 8.3%。

受訪企業示例

  • Advin Health Care
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Cipla Ltd.
  • ARKRAY, Inc.
  • Gerresheimer AG
  • A. Menarini Diagnostics Srl
  • Exelint International Co.
  • Hindustan Syringes & Medical Devices Ltd.
  • Allison Medical, Inc.
  • HTL-Strefa SA
  • GlucoRx Ltd.
  • Cambridge Sensors Ltd.
  • Igaku Needles Private Limited
  • AdvaCare Pharma

目錄

第1章 調查方法

第2章 執行摘要

  • 市場概況
  • 世界品牌
  • 主要企業
  • 市場趨勢和促進因素
  • 宏觀成長動力
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳大利亞
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 競爭

簡介目錄
Product Code: MCP22487

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Pen Needles Market to Reach $4.8 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Pen Needles estimated at US$2.4 Billion in the year 2022, is projected to reach a revised size of US$4.8 Billion by 2030, growing at aCAGR of 9.2% over the period 2022-2030. Standard, one of the segments analyzed in the report, is projected to record 7.2% CAGR and reach US$2.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Safety segment is readjusted to a revised 11.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $769.1 Million, While China is Forecast to Grow at 10.3% CAGR

The Pen Needles market in the U.S. is estimated at US$769.1 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$381.7 Million by the year 2030 trailing a CAGR of 10.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.9% and 8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Select Competitors (Total 63 Featured) -

  • Advin Health Care
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Cipla Ltd.
  • ARKRAY, Inc.
  • Gerresheimer AG
  • A. Menarini Diagnostics Srl
  • Exelint International Co.
  • Hindustan Syringes & Medical Devices Ltd.
  • Allison Medical, Inc.
  • HTL-Strefa SA
  • GlucoRx Ltd.
  • Cambridge Sensors Ltd.
  • Igaku Needles Private Limited
  • AdvaCare Pharma

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of COVID-19 and a Looming Global Recession
    • The Never-Ending "Race" Between the Virus & Vaccines Continues. Amidst this Chaotic Battle, Where is the World Economy Heading Now & Beyond?
    • Omicron Variant Brings Back Memories & Fears of the Worst Part of the 2020 Pandemic
    • Time is of Essence! What We Know So Far - "Vaccine Efficiency Against New Strains"
    • With New Strains Emerging at an Alarming Rate, Focus Shifts to Booster Doses & Vaccine Tweaking. But How Practical Is It to Implement Them?
    • With Vaccinated Population Showing Signs of Declining Clinical Protection, Booster Doses Are Emerging Into a Necessity to Restore Vaccine Effectiveness: Number of Booster Doses Administered Per 100 People by Country as of December 2021
    • How Healthcare Has Been Impacted & Beyond COVID-19 What's In Store for Healthcare?
    • Missed Cancer Diagnosis in U.S. as of June 2020
    • % Reduction in OR Volumes in the US: Mar 2020-July 2020
    • Cumulative Surgery Cancellations Worldwide (In Million)
    • With the COVID-19 Pandemic Exposing Global Healthcare Unpreparedness, There is Increasing Policy Led Focus on Rebooting Health Systems Worldwide: Current & Required Healthcare Spending as % of GDP
    • COVID-19 and Elective Surgeries
    • COVID-19 Impact on Pen Needles Market
    • Competition
    • Pen Needles - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Market Players Worldwide in 2022 (E)
    • Needles: A Prelude
    • Types of Needles
    • An Insight into Pen Needles
    • Pen Needles for Insulin Injection
    • Global Market Analysis and Prospects
    • Global Pen Needles Market Set for a Rapid Growth
    • Standard Pen Needles Dominate, Safety Pen Needles to Witness Fastest Growth
    • Emerging Markets: Focal Point for Future Growth
    • Competitive Landscape
    • Top Pen Needle Products
    • Recent Market Activity
  • WORLD BRANDS
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rise in Diabetic Population Continues to Drives Demand for Pen Needles
    • World Diabetes and Population Statistics (2019, 2030 & 2045)
    • Global Prevalence of Diabetes: Number of Adults Diagnosed with Diabetes (in Million) by Gender for 2019, 2030 and 2045
    • World Diabetes Prevalence (2000-2019)
    • Top 10 Countries with Highest Number of Adults Diagnosed with Diabetes (in Million) for 2019 and 2045
    • Global Diabetes Mellitus Population Breakdown by Geographic Region: 2019, 2030 and 2045?
    • Diabetes Emerges as One of the Leading Causes of Mortality
    • Diabetes-Related Deaths as % of Total Deaths in Below 60 Years Population by Region: 2019
    • Growing Prevalence of Chronic Diseases Drive the Demand for Pen Needles
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
    • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • High Risk of Diabetes in the Fast Expanding Aging Population Benefit Market Expansion
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Pen Needles Gain Traction as Insulin Pens Rise in Popularity for Administering Insulin
    • Smart Insulin Pens: A Growing Area of Interest
    • Increasing Role of Self-Injection Devices in Diabetes Management
    • Needle-Free Alternatives: A Growing Threat
    • Innovative Technologies Revolutionize Pen Needles Market
    • Advancements in Insulin Delivery Methods Drive the Demand for Pen Needles
    • Advancements in Pen Needle Technology
    • Droplet Micron Insulin Needle Represents Innovation in the Diabetes Supply Market
  • MACRO GROWTH DRIVERS
    • Increasing Healthcare Expenditure Aids Pen Drives Market Growth
    • World Healthcare Expenditure (In US$ Trillion) for the Years for 2017, 2019, 2021, 2023
    • Increasing Obesity Levels Underpins Market Growth
    • Average Per Capita Annual Health Expenditure (In US$) due to Obesity
    • Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
    • Rising Demand for Biosimilar Drugs Propel the Market for Pen Needles
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Pen Needles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Standard by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Standard by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Standard by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Safety by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 19: World Pen Needles Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • JAPAN
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • CHINA
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 40: China 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 43: China 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • EUROPE
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Pen Needles by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • FRANCE
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 55: France 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 58: France 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • GERMANY
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Pen Needles by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • INDIA
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 112: India 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 115: India 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Pen Needles by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Pen Needles by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030
  • AFRICA
    • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2023 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2023 & 2030

IV. COMPETITION